EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Recent Developments and Structure–Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery

Xin-Ke Guo, Kadalipura P Rakesh iD, Sahana Raju, Kothanahally S Sharath Kumar iD, Hua-Li Qin

Archiv der Pharmazie · 2026-08 · 359 (8)

DOI: 10.1002/ardp.70322 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 20.08.2026. Verfasst von Xin-Ke Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan, People's Republic of China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Drug Discovery, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the National Natural Science Foundation of China, the Wuhan University of Technology for their support.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Incorporating current structural and biochemical discoveries, this paper examines how B‐RAF inhibitors control B‐RAF, including their clinical efficacy, side effects, and important medicinal chemistry characteristics. It investigates the molecular insights that may direct the creation of more potent RAF inhibitors that can target different oncogenic B‐RAF conformations. We have discussed the advantages and disadvantages of structurally varied next‐generation RAF inhibitors that are presently undergoing preclinical and clinical trials. A few of these drug candidates have started clinical trials with promising outcomes. This review also covers the structure–activity relationship of promising bioactive B‐RAF compounds, highlights advancements in the discovery and development of B‐RAF inhibitors, and attempts to assist future drug discovery initiatives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafDrug DiscoveryProtein Kinase InhibitorsAntineoplastic AgentsNeoplasmsHumansStructure-Activity RelationshipAnimalsMolecular Structure

Stichwörter der Autor:innen

BRAF inhibitorSARdrug discovery

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsAntineoplastic AgentsBRAF protein, human

Autor:innen und Institutionen

  • School of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan, People's Republic of China.
  • Department of Physics, GSSS Institute of Engineering and Technology for Women, Metagalli, Mysuru, Visvesvaraya Technological University, Belagavi, Mysuru, Karnataka, India.
  • Department of Studies in Chemistry, Manasagangotri, University of Mysore, Mysuru, India.

ORCID-Profile: Kadalipura P Rakesh, Kothanahally S Sharath Kumar

Förderung

  • the National Natural Science Foundation of China
  • the Wuhan University of Technology for their support

Zitieren

APA

Guo, X. K., Rakesh, K. P., Raju, S., Sharath Kumar, K. S., & Qin, H. L. (2026). Recent Developments and Structure–Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery. Archiv der Pharmazie, 359(8). https://doi.org/10.1002/ardp.70322

Vancouver

Guo XK, Rakesh KP, Raju S, Sharath Kumar KS, Qin HL. Recent Developments and Structure–Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery. Archiv der Pharmazie. 2026;359(8). doi:10.1002/ardp.70322

BibTeX
@article{Guo2026,
  author = {Guo, Xin-Ke and Rakesh, Kadalipura P and Raju, Sahana and Sharath Kumar, Kothanahally S and Qin, Hua-Li},
  title = {Recent Developments and Structure–Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery},
  journal = {Archiv der Pharmazie},
  year = {2026},
  volume = {359},
  number = {8},
  doi = {10.1002/ardp.70322}
}
Kostenlos starten →